Guardian Capital LP Sells 19,768 Shares of Kenvue Inc. (NYSE:KVUE)

Guardian Capital LP cut its stake in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 4.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 447,146 shares of the company’s stock after selling 19,768 shares during the period. Guardian Capital LP’s holdings in Kenvue were worth $9,627,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in KVUE. Clearstead Advisors LLC bought a new stake in shares of Kenvue during the 3rd quarter worth approximately $25,000. Planned Solutions Inc. bought a new stake in Kenvue during the fourth quarter worth about $27,000. Venturi Wealth Management LLC bought a new position in Kenvue in the 3rd quarter valued at about $28,000. EverSource Wealth Advisors LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at approximately $28,000. Finally, Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Kenvue during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock traded up $0.27 during mid-day trading on Tuesday, hitting $20.63. 21,283,723 shares of the company traded hands, compared to its average volume of 17,163,033. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The stock has a market cap of $39.50 billion and a price-to-earnings ratio of 26.45. The stock has a fifty day moving average price of $20.00 and a 200-day moving average price of $20.16.

Kenvue (NYSE:KVUEGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The business’s revenue was down 24.9% compared to the same quarter last year. On average, equities analysts predict that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be paid a $0.20 dividend. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.88%. Kenvue’s dividend payout ratio (DPR) is 102.56%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective for the company. Sanford C. Bernstein began coverage on shares of Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Royal Bank of Canada cut their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, HSBC increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $24.38.

View Our Latest Stock Analysis on Kenvue

About Kenvue

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Further Reading

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.